Kailera Therapeutics said its oral GLP-1 asset achieved primary endpoints in two Phase 3 obesity and diabetes trials in China, supporting Hengrui Pharma’s path to regulatory submissions. The trials read out 11% weight loss and met key efficacy goals in the obesity study, while the diabetes program posted encouraging efficacy results. Separate reports on the late-stage programs highlighted gastrointestinal side effects as a key safety concern for the daily oral therapy, with analysts pointing to tolerability as the major differentiator to watch against injectable GLP-1s. The topline results strengthen the competitive outlook for oral incretin approaches in China, where oral formulations may benefit adherence and broaden eligibility. The next milestone will be whether the safety profile sustains through registrational datasets. For Hengrui, the clinical readouts add momentum to its specialization in metabolic disease drug development and increase pressure on competitors to show oral-efficacy and tolerability advantages.